Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Orchid Island Capital Inc (ORC), Sarepta Therapeutics Inc (SRPT) & First Bancorp (FBP) Plunging: Were Hedge Funds Right About These Stocks?

Page 1 of 2

Small-cap stocks Orchid Island Capital Inc (NYSE:ORC), Sarepta Therapeutics Inc (NASDAQ:SRPT) and First Bancorp (NYSE:FBP) have all dropped by more than 8% so far today. The specialty finance company Orchid Island Capital Inc (NYSE:ORC) has dropped around 8% so far. Medical research company Sarepta Therapeutics Inc (NASDAQ:SRPT) has also lost around 8%, while Maine’s community bank First Bancorp (NYSE:FBP) has lost around 15% since the markets opened this morning. Why was there a huge drop in these stocks and what do hedge funds think about them? Let’s look for the answers.


We track hedge fund and insider activity on stocks mainly to get the perspectives on the stock from the brightest and most knowledgeable minds in the world. Hedge fund managers can use their vast experience to give us a better insight into the stock, but insiders always have that little bit of additional information about a stock, well before the portfolio managers and analysts know about it. So it is very important to keep track of both of these metrics on a stock. Hedge funds have been underperforming the market for a very long time. However, this was mainly because of the huge fees that hedge funds charge as well as the poor performance of their short books. Hedge funds’ long positions actually performed better than the market. Small-cap stocks, activist targets, and spin-offs were among the bright spots in hedge funds’ portfolios. For instance, the 15 most popular small-cap stocks among hedge funds outperformed the market by more than 85 percentage points since the end of August 2012, returning over 145% (read the details here). This strategy also managed to beat the market by double digits annually in our back tests covering the 1999-2012 period.

Orchid Island Capital Inc (NYSE:ORC) has dropped around 8% so far today mainly due to the nature of its business and the fact that Mortgage REIT’s remain under pressure. The smallest companies in the sector like Orchid Island Capital and a few others were hit hard today. Orchid Island Capital has also plunged 7% in the last week and around 11% in the last four weeks. But what do hedge funds think about this stock?

At the end of the first quarter, a total of six of the hedge funds were holding long position in Orchid Island Capital Inc (NYSE:ORC), a change of 20% from the fourth quarter. But this does not mean that hedge funds were bullish on this stock, because the aggregate capital invested by these hedge funds dropped by 12% to $4.5 million in the first three months of this year. On the contrary the stock had gained about 1.3% in the first three months. This clearly shows that hedge funds were not bullish on the stock, despite the fact that the overall number of hedge funds holding positions in the stock increased. David  E. Shaw‘s D E Shaw holds the largest position in the stock, of around 111,301 shares valued at $1.5 million at the end of the first quarter. But D E Shaw had 195,000 shares valued at $2.5 million at the end of the fourth quarter. Speaking about insider activity on the stock, there was no insider sales of the stock in the last few months, but there were a few insider purchases. Orchid Island Capital CEO Robert Cauley purchased around 3,000 shares in the first quarter. This shows that insiders were bullish on the stock.

David E. Shaw
David E. Shaw
D E Shaw

Medical research and drug development company, Sarepta Therapeutics Inc (NASDAQ:SRPT) lost around 8% of its value so far today. The stock had gained in triple digits (110%) in the month since it had updated the status of its lead drug eteplirsen for Duchenne muscular dystrophy. But why did the stock lose around 8% today? Sarepta announced earlier an agreement with Midcap Financial to borrow up to $40 million at an annual rate of 7.75%. This debt financing deal has apparently not impressed investors, who reacted by selling down the stock from its massive highs. Lets take a look at how hedge funds traded this stock.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!